S
Susan H. Fox
Researcher at University of Toronto
Publications - 220
Citations - 17609
Susan H. Fox is an academic researcher from University of Toronto. The author has contributed to research in topics: Dyskinesia & Parkinson's disease. The author has an hindex of 56, co-authored 208 publications receiving 14500 citations. Previous affiliations of Susan H. Fox include University of Manchester & University Health Network.
Papers
More filters
Journal ArticleDOI
The Relationship Between Serotonin-2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations
Sang Soo Cho,Sang Soo Cho,Antonio P. Strafella,Antonio P. Strafella,Sarah Duff-Canning,Mateusz Zurowski,Anne Catherine Vijverman,Veronica Bruno,Camila C. Aquino,Marion Criaud,Marion Criaud,Pablo Rusjan,Sylvain Houle,Susan H. Fox +13 more
TL;DR: The objective of this study was to investigate the level of serotonin 2A receptor availability in brain regions affected by visual hallucinations and to test the association with cognitive/behavioral changes in patients who have PD with visual hallucinations.
Journal ArticleDOI
Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
Achinoam Faust-Socher,Achinoam Faust-Socher,Sarah Duff-Canning,Arthur Grabovsky,Melissa J. Armstrong,Brandon Rothberg,Paul J. Eslinger,Christopher Meaney,Ruth B. Schneider,David F. Tang-Wai,Susan H. Fox,Cindy Zadikoff,Nancy Kennedy,Kelvin L. Chou,Carol Persad,Irene Litvan,Benjamin T. Mast,Adam Gerstenecker,Sandra Weintraub,William Reginold,Connie Marras,Connie Marras +21 more
TL;DR: The performance of the MoCA, MMSE, and SCOPA-Cog for detecting decline in non-demented PD patients over a 1-year interval is poor and has implications for clinical practice; stable scores may not be taken as reassurance of the absence of cognitive decline.
Journal ArticleDOI
Diagnostic delay in Parkinson's disease caused by PRKN mutations
Marta Ruiz-Lopez,Maria Eliza Freitas,Lais M. Oliveira,Renato P. Munhoz,Susan H. Fox,Mohammad Rohani,Ekaterina Rogaeva,Anthony E. Lang,Alfonso Fasano,Alfonso Fasano,Alfonso Fasano +10 more
TL;DR: A specific phenotype associated with a diagnostic delay is identified: young age, lack of tremor, and involvement of lower limbs (particularly dystonia affecting gait) at the time of disease onset.
Journal ArticleDOI
Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease.
Veronica Bruno,Maria Eliza Freitas,Deborah A Mancini,Jane P. Lui,Janis M. Miyasaki,Janis M. Miyasaki,Susan H. Fox +6 more
TL;DR: Targeted BTXA injections were safe in patients with limb pain and advanced PD; however, the present study failed to show a significant effect when compared to placebo.
Journal ArticleDOI
Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease
TL;DR: Reduction and discontinuation of anticholinergics, amantadine, dopamine agonists, and levodopa as tolerated, as well as adjunctive clozapine or quetiapine are frequently effective to manage Parkinson disease psychosis.